<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Fam Pract</journal-id><journal-id journal-id-type="iso-abbrev">BMC Fam Pract</journal-id><journal-title-group><journal-title>BMC Family Practice</journal-title></journal-title-group><issn pub-type="epub">1471-2296</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24885192</article-id><article-id pub-id-type="pmc">4045910</article-id><article-id pub-id-type="publisher-id">1471-2296-15-104</article-id><article-id pub-id-type="doi">10.1186/1471-2296-15-104</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Safety relevant knowledge of orally anticoagulated patients without self-monitoring: a baseline survey in primary care</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Chenot</surname><given-names>Jean-Fran&#x000e7;ois</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>jchenot@uni-greifswald.de</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Hua</surname><given-names>Thanh Duc</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>docHua.TD@gmail.com</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Abu Abed</surname><given-names>Manar</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>manar.abuabed@med.uni-goettingen.de</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Schneider-Rudt</surname><given-names>Hannelore</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>hschnei4@gwdg.de</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Friede</surname><given-names>Tim</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>Tim.Friede@med.uni-goettingen.de</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Schneider</surname><given-names>Simon</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>simon.schneider@med.uni-goettingen.de</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Vormfelde</surname><given-names>Stefan Viktor</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>svormfe@gwdg.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of General Practice, Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany</aff><aff id="I2"><label>2</label>Department of General Practice, University Medical Center G&#x000f6;ttingen, G&#x000f6;ttingen, Germany</aff><aff id="I3"><label>3</label>Department of Medical Statistics, University Medical Center G&#x000f6;ttingen, G&#x000f6;ttingen, Germany</aff><aff id="I4"><label>4</label>Institute of Clinical Pharmacology, University Medical Center G&#x000f6;ttingen, Robert-Koch-Str. 40, D-37075 G&#x000f6;ttingen, Germany</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>25</day><month>5</month><year>2014</year></pub-date><volume>15</volume><fpage>104</fpage><lpage>104</lpage><history><date date-type="received"><day>13</day><month>1</month><year>2014</year></date><date date-type="accepted"><day>20</day><month>5</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Chenot et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Chenot et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2296/15/104"/><abstract><sec><title>Background</title><p>Effective and safe management of oral anticoagulant treatment (OAT) requires a high level of patient knowledge and adherence. The aim of this study was to assess patient knowledge about OAT and factors associated with patient knowledge.</p></sec><sec><title>Methods</title><p>This is a baseline survey of a cluster-randomized controlled trial in 22 general practices with an educational intervention for patients or their caregivers. We assessed knowledge about general information on OAT and key facts regarding nutrition, drug-interactions and other safety precautions of 345 patients at baseline.</p></sec><sec><title>Results</title><p>Participants rated their knowledge about OAT as excellent to good (56%), moderate (36%) or poor (8%). However, there was a discrepancy between self-rated knowledge and evaluated actual knowledge and we observed serious knowledge gaps. Half of the participants (49%) were unaware of dietary recommendations. The majority (80%) did not know which non-prescription analgesic is the safest and 73% indicated they would not inform pharmacists about OAT. Many participants (35-75%) would not recognize important emergency situations. After adjustment in a multivariate analysis, older age and less than 10&#x000a0;years education remained significantly associated with lower overall score, but not with self-rated knowledge.</p></sec><sec><title>Conclusions</title><p>Patients have relevant knowledge gaps, potentially affecting safe and effective OAT. There is a need to assess patient knowledge and for structured education programs.</p></sec><sec><title>Trial registration</title><p>Deutsches Register Klinischer Studien (German Clinical Trials Register): <ext-link ext-link-type="uri" xlink:href="https://drks-neu.uniklinik-freiburg.de/drks_web/navigate.do?navigationId=trial.HTML&#x00026;TRIAL_ID=DRKS00000586">DRKS00000586</ext-link>.</p><p>Universal Trial Number (<ext-link ext-link-type="uri" xlink:href="http://apps.who.int/trialsearch/trial.aspx?trialid=DRKS00000586">UTN U1111-1118-3464</ext-link>).</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Thrombosis and atrial fibrillation are the major indications for oral anticoagulation therapy (OAT). Due to an increase in aging population, the number of adults with atrial fibrillation will increase considerably. Consequently, a global increase in the number of patients requiring OAT is expected over the next decades [<xref ref-type="bibr" rid="B1">1</xref>]. The effectiveness of OAT to reduce risk of stroke or recurrent thrombosis has been proven and OAT is recommended in guidelines [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. Frequently used drugs for OAT are warfarin, phenprocoumon and acenocoumarol. Studies have shown that insufficient adherence and a low level of patient knowledge about OAT are the primary causes for complications [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. OAT thus requires regular monitoring of the international normalized ratio (INR) and dose adjustments, as well as a high level of patient knowledge and adherence to recommendations on nutrition, medication and recognition of critical situations. Bleeding complications occur in 0.3 to 0.4% of all patients with OAT every year, but risk estimates vary widely [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. While educational programs, self-monitoring and self-management of OAT have been established this is not suitable for many patients [<xref ref-type="bibr" rid="B9">9</xref>]. Standardized education programs for patients without self-monitoring are lacking in many countries [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. The best strategy to educate patients about oral anticoagulation has not been determined yet [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. In Germany, general practitioners manage the majority of patients with OAT, there are no coagulation clinics. Some general practitioners use self-written patient information brochures to inform patients about OAT. Content and quality of these brochures is heterogeneous and sometimes inaccurate. It is known that information brochures on OAT require reading levels, exceeding the capacity of many patients [<xref ref-type="bibr" rid="B12">12</xref>].</p><p>The aim of this study was to assess patients&#x02019; knowledge about OAT and factors associated with patient knowledge.</p></sec><sec sec-type="methods"><title>Methods</title><p>This is a baseline survey within a cluster-randomized controlled study conducted in 22 general practices in Germany. The Ethics Committee of the medical school of the University of G&#x000f6;ttingen approved this study. A detailed study protocol has been published [<xref ref-type="bibr" rid="B13">13</xref>].</p><sec><title>Recruitment of practices and patients</title><p>A total of 22 general practices out of 85 practices agreed to participate in the study (2 practices did not exist anymore, 3 were put on a waiting list). Addresses were obtained from the local Association of Statutory Health Insurance Physicians (Kassen&#x000e4;rztliche Vereinigung). The GPs (n&#x02009;=&#x02009;32) were on average 12.7&#x000a0;years in practice (SD&#x02009;&#x000b1;&#x02009;6.9), 49&#x000a0;years old (SD&#x02009;&#x000b1;&#x02009;6) (national average 50.4&#x000a0;years) and 52% of them were female (national average 38%). A total of 18 (80%) practices were run by a single GP. The study was conducted in two medium size university cities (5 practices) and surrounding small towns (10 practices) and rural areas (7 practices), thus being representative for most parts of Germany except for large cities. All, but one of the practices were part of the educational network of the university.The 986 patients receiving OAT with phenprocoumon, which is the drug most widely used in Germany for OAT, were identified by searching the GPs&#x02019; electronic medical records for the laboratory billing code for INR measurement. The inclusion criteria were age (&#x02265;18&#x000a0;years), receiving OAT and willingness to participate in the study. For patients not managing OAT themselves, their caregivers were invited to participate as a substitute but will not be reported here. Exclusion criteria were: inability to give informed consent, management of anticoagulation with self-monitoring (PSM), nursing home residency, insufficient command of German and patients only seen in cross coverage. New oral anticoagulation agents like dabigatran and rivaroxaban had entered the European market in August and December 2011, respectively, and were therefore rarely used during the time of patient recruitment in 2010&#x02013;11. A total of 577 patients, representing 59% of all potentially eligible patients, were contacted by the practice nurse in order to fix an appointment for INR control. Finally, 345 patients were included in the study. The recruitment is shown in Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Recruitment flow.</p></caption><graphic xlink:href="1471-2296-15-104-1"/></fig></sec><sec><title>Data collection</title><p>Demographic data of the participants and patient knowledge about OAT were collected at baseline with a self-developed questionnaire based on models from the literature [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. We chose to use a self-developed questionnaire, because we felt that existing instruments were not comprehensive enough or were not sufficiently adaptable to the specific situation in Germany. The questionnaire evaluated patient knowledge about general information on OAT, and relevant facts regarding nutrition, drug-interactions and other safety precautions such as recognition of complications and informing health care professionals about OAT. Questions were based mainly on relevant national guidelines and expert knowledge [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. The questionnaire was piloted previously with 12 patients in a practice, which did not participate in the trial using the think aloud technique [<xref ref-type="bibr" rid="B17">17</xref>] and optimized accordingly to ensure comprehensibility.</p><p>An English version of the questionnaire is available online [<xref ref-type="bibr" rid="B13">13</xref>]. Participants had to fill out the questionnaire themselves under supervision in the practice, without any assistance. Patient names and other confidential information were coded to make it difficult to track individual patients. Informed consent and questionnaires were returned to the study center separately by the practice.</p></sec><sec><title>Statistical analysis</title><p>Categorical data were summarized as frequencies and percentages, quantitative variables as medians and interquartile ranges (IQR). For the 13-item knowledge score, all thirteen questions were weighted equally with one point. The total-sum score ranges from 0 to 13, with higher scores indicating greater knowledge.</p><p>For questions with multiple yes/no answers the one point awarded to the question in total was divided across all answers. Correct answers received twice the weight of incorrect answers. Indicating &#x0201c;I don&#x02019;t know&#x0201d; led to 0 points irrespective of which other correct or incorrect answers were ticked. For instance, in question 12 the first four answers were correct, the fifth answer was incorrect, the sixth was &#x0201c;I don&#x02019;t know&#x0201d;. The four correct answers were weighted by 2/9 points each. The fifth answer which was incorrect carried a weight of 1/9. &#x0201c;I don&#x02019;t know&#x0201d; carried no weight. For example ticking the first four answers in question 12 gave the maximum score of 1 point. Ticking the first five answers was awarded 8/9 points. Ticking all six answers resulted in no point at all.</p><p>To explore factors associated with the score we conducted univariate and multiple regression analyses fitting linear mixed effects models with age, gender, years of education (dichotomized to &#x0201c;less&#x0201d; and &#x0201c;more or equal&#x0201d; than 10&#x000a0;years), fear of bleeding, history of prior OAT related complications, self-rated knowledge as fixed effects, and practice as random effect. The latter accounted for possible correlations between patients from the same practice and thereby adjusted for possible cluster effects. SAS 9.3 (SAS, Cary, NC) was used for statistical analysis. P-values were not adjusted for multiplicity and p-values smaller than 0.05 are referred to as statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Participants&#x02019; characteristics</title><p>Of the 345 patients, roughly half (163; 47%) were women. The median age of the participants was 74&#x000a0;years (IQR: 68&#x02013;78) and 253 participants (73%) had an educational level of less than 10&#x000a0;years of school education (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>). The most common indication for OAT was atrial fibrillation (70%). Patients receiving oral anticoagulants for recurrent thrombosis or pulmonary embolism were younger than those with atrial fibrillation: 75&#x000a0;years (IQR 69&#x02013;79) versus 72 (IQR 63&#x02013;78) years. A total of 9% of the participants reported previous complications related to OAT. More than half (54%) of all participants were afraid of complications related to OAT (Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>). To assess for presence of selection bias we compared age and gender between patients finally enrolled in the study, patients declining to participate and patients who were contacted by the practice. There were no statistically significant differences (results not shown).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Socio-demographic and clinical characteristics (n&#x02009;=&#x02009;345)</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left"><bold>Socio-demographic characteristics</bold></th><th align="center"><bold>n (%)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold>Gender</bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;Women<hr/></td><td align="center" valign="bottom">163 (47%)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;Men<hr/></td><td align="center" valign="bottom">182 (53%)<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Age</bold> (median/IQR***)<hr/></td><td align="center" valign="bottom">74&#x000a0;years (68&#x02013;78)<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Education*</bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;&#x0003c; 10&#x000a0;years education<hr/></td><td align="center" valign="bottom">253 (73%)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;&#x02265; 10&#x000a0;years education<hr/></td><td align="center" valign="bottom">92 (27%)<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Indication for oral anticoagulation according to the patient**</bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;Atrial fibrillation<hr/></td><td align="center" valign="bottom">239 (70%)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;Deep vein thrombosis<hr/></td><td align="center" valign="bottom">70 (21%)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;Pulmonary embolism<hr/></td><td align="center" valign="bottom">35 (10%)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;Artificial heart valve<hr/></td><td align="center" valign="bottom">22 (6%)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;Unknown to the patient<hr/></td><td align="center" valign="bottom">16 (5%)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;Missing<hr/></td><td align="center" valign="bottom">5 (1%)<hr/></td></tr><tr><td align="left" valign="bottom"><bold>OAT related complication in history</bold><hr/></td><td align="center" valign="bottom">29 (9%)<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Self-rated knowledge about OAT</bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;Excellent<hr/></td><td align="center" valign="bottom">31 (9%)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;Good<hr/></td><td align="center" valign="bottom">162 (47%)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;Moderate<hr/></td><td align="center" valign="bottom">122 (36%)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;Poor<hr/></td><td align="center" valign="bottom">27 (8%)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;Missing<hr/></td><td align="center" valign="bottom">3 (1%)<hr/></td></tr><tr><td align="left"><bold>Afraid of complications</bold></td><td align="center">182 (54%)</td></tr></tbody></table><table-wrap-foot><p>*&#x02009;&#x0003c;&#x02009;10&#x000a0;years corresponds to lowest educational level, more than 10&#x000a0;years to a medium to high educational level.</p><p>**Multiple indications for oral anticoagulation therapy (OAT) possible.</p><p>*** IQR = interquartile range.</p></table-wrap-foot></table-wrap></sec><sec><title>Patient knowledge</title><p>Most participants knew their indication for OAT (95%) and how frequently their coagulation status should be controlled (82%), but in most other areas we observed substantial knowledge gaps (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>). A total of 80% of participants did not know which non-prescription analgesic is the safest option for them and 17% indicated they would take non-steroidal anti-inflammatory drugs (NSAIDs). 68% of participants did not know that they had to follow a specific diet. Women had a slightly better knowledge on questions regarding nutrition. Most of the participants were not aware that gastroenteritis, fasting, or non-prescription medicines, could affect the effectiveness of OAT (82%, 86% and 79%, respectively). Many participants were not aware of complications of over- and under-dosing. For example, paresis and melaena were not considered an emergency by 74% and 60% of the participants, respectively (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>). Most participants (88%) indicated they would inform health professionals about their OAT before undergoing planned invasive medical procedures. However, 72% of the participants would not inform their pharmacists about OAT.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Answers to questionnaire assessing knowledge on oral anticoagulation therapy (n&#x02009;=&#x02009;345)</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left"><bold>#</bold></th><th align="left">&#x000a0;</th><th align="center"><bold>Correct answer</bold></th><th align="center"><bold>Correct n (%)</bold></th><th align="center"><bold>Incorrect* n (%)</bold></th><th align="center"><bold>Score</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">1<hr/></td><td align="left" valign="bottom">Indication for OAT known<hr/></td><td align="center" valign="bottom">Individual<hr/></td><td align="center" valign="bottom">329 (95%)<hr/></td><td align="center" valign="bottom">16 (5%)<hr/></td><td align="center" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">2<hr/></td><td align="left" valign="bottom">Awareness of risk treated with OAT<hr/></td><td align="center" valign="bottom">Individual<hr/></td><td align="center" valign="bottom">278 (81%)<hr/></td><td align="center" valign="bottom">67 (19%)<hr/></td><td align="center" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">3<hr/></td><td align="left" valign="bottom">Duration of treatment known<hr/></td><td align="center" valign="bottom">Individual<hr/></td><td align="center" valign="bottom">249 (72%)<hr/></td><td align="center" valign="bottom">96 (28%)<hr/></td><td align="center" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">4<hr/></td><td align="left" valign="bottom">Frequency of controls known<hr/></td><td align="center" valign="bottom">Individual<hr/></td><td align="center" valign="bottom">278 (81%)<hr/></td><td align="center" valign="bottom">67 (19%)<hr/></td><td align="center" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">5<hr/></td><td align="left" valign="bottom">Awareness of target INR range<hr/></td><td align="center" valign="bottom">Individual<hr/></td><td align="center" valign="bottom">158 (46%)<hr/></td><td align="center" valign="bottom">187 (54%)<hr/></td><td align="center" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">6<hr/></td><td align="left" valign="bottom">Need to follow a specific diet<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Overall<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">107 (31%)<hr/></td><td align="center" valign="bottom">238 (69%)<hr/></td><td align="center" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Consuming large amounts of salad and vegetables<hr/></td><td align="center" valign="bottom">No<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">11 (3%)<hr/></td><td align="center" valign="bottom">0<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Avoid salad and vegetables<hr/></td><td align="center" valign="bottom">No<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">57 (17%)<hr/></td><td align="center" valign="bottom">0<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Regular diet of salad and vegetables<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">107 (31%)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Do not know<hr/></td><td align="center" valign="bottom">No<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">170 (49%)<hr/></td><td align="center" valign="bottom">0<hr/></td></tr><tr><td align="left" valign="bottom">7<hr/></td><td align="left" valign="bottom">Vitamin K content of some foods<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Overall<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Cabbage<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">245 (71%)<hr/></td><td align="center" valign="bottom">100 (29%)<hr/></td><td align="center" valign="bottom">1/8<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Potatoes<hr/></td><td align="center" valign="bottom">No<hr/></td><td align="center" valign="bottom">283 (82%)<hr/></td><td align="center" valign="bottom">62 (18%)<hr/></td><td align="center" valign="bottom">1/8<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Apples<hr/></td><td align="center" valign="bottom">No<hr/></td><td align="center" valign="bottom">284 (82%)<hr/></td><td align="center" valign="bottom">61 (18%)<hr/></td><td align="center" valign="bottom">1/8<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Green salad<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">155 (45%)<hr/></td><td align="center" valign="bottom">190 (55%)<hr/></td><td align="center" valign="bottom">1/8<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Tomato extract<hr/></td><td align="center" valign="bottom">No<hr/></td><td align="center" valign="bottom">260 (75%)<hr/></td><td align="center" valign="bottom">85 (25%)<hr/></td><td align="center" valign="bottom">1/8<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Spinach<hr/></td><td align="center" valign="bottom">No<hr/></td><td align="center" valign="bottom">164 (48%)<hr/></td><td align="center" valign="bottom">181 (52%)<hr/></td><td align="center" valign="bottom">1/8<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Onion<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">37 (11%)<hr/></td><td align="center" valign="bottom">308 (89%)<hr/></td><td align="center" valign="bottom">1/8<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Zucchini<hr/></td><td align="center" valign="bottom">No<hr/></td><td align="center" valign="bottom">268 (78%)<hr/></td><td align="center" valign="bottom">77 (22%)<hr/></td><td align="center" valign="bottom">1/8<hr/></td></tr><tr><td align="left" valign="bottom">8<hr/></td><td align="left" valign="bottom">Management of missed medication dose<hr/></td><td align="center" valign="bottom">n.a.<hr/></td><td align="center" valign="bottom">46 (13%)<hr/></td><td align="center" valign="bottom">299 (87%)<hr/></td><td align="center" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">9<hr/></td><td align="left" valign="bottom">Awareness that there are no symptoms of underdosing<hr/></td><td align="center" valign="bottom">n.a.<hr/></td><td align="center" valign="bottom">194 (56%)<hr/></td><td align="center" valign="bottom">151 (44%)<hr/></td><td align="center" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">10<hr/></td><td align="left" valign="bottom">Safest over the counter pain medication<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Overall<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">68 (20%)<hr/></td><td align="center" valign="bottom">277 (80%)<hr/></td><td align="center" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Paracetamol/acetaminophen<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">68 (20%)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Aspirin (acetylsalicylic acid)<hr/></td><td align="center" valign="bottom">No<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">21 (6%)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Other non-steroidal anti-inflammatory drugs<hr/></td><td align="center" valign="bottom">No<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">37 (11%)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Do not know<hr/></td><td align="center" valign="bottom">No<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">219 (63%)<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">11<hr/></td><td align="left" valign="bottom">Interaction with OAT<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Overall<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Regular exercise<hr/></td><td align="center" valign="bottom">No<hr/></td><td align="center" valign="bottom">264 (77%)<hr/></td><td align="center" valign="bottom">81 (23%)<hr/></td><td align="center" valign="bottom">1/8<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Gastroenteritis<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">60 (17%)<hr/></td><td align="center" valign="bottom">285 (83%)<hr/></td><td align="center" valign="bottom">1/8<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Fever<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">16 (5%)<hr/></td><td align="center" valign="bottom">328 (95%)<hr/></td><td align="center" valign="bottom">1/8<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Coffee<hr/></td><td align="center" valign="bottom">No<hr/></td><td align="center" valign="bottom">327 (95%)<hr/></td><td align="center" valign="bottom">18 (5%)<hr/></td><td align="center" valign="bottom">1/8<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Ginkgo biloba<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">16 (5%)<hr/></td><td align="center" valign="bottom">329(95%)<hr/></td><td align="center" valign="bottom">1/8<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Non-prescription drugs<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">71 (21%)<hr/></td><td align="center" valign="bottom">274 (79%)<hr/></td><td align="center" valign="bottom">1/8<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Moderate intake of alcohol<hr/></td><td align="center" valign="bottom">No<hr/></td><td align="center" valign="bottom">272 (79%)<hr/></td><td align="center" valign="bottom">73 (21%)<hr/></td><td align="center" valign="bottom">1/8<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Fasting/weight reduction diet<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">48 (14%)<hr/></td><td align="center" valign="bottom">297 (86%)<hr/></td><td align="center" valign="bottom">1/8<hr/></td></tr><tr><td align="left" valign="bottom">12<hr/></td><td align="left" valign="bottom">Recognition of emergency situations<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Overall<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Painful swelling with or without skin discoloration<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">95 (28%)<hr/></td><td align="center" valign="bottom">250 (72%)<hr/></td><td align="center" valign="bottom">1/5<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Sudden speech disorder<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">169 (49%)<hr/></td><td align="center" valign="bottom">176 (51%)<hr/></td><td align="center" valign="bottom">1/5<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Black stool (melaena)<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">133 (39%)<hr/></td><td align="center" valign="bottom">212 (61%)<hr/></td><td align="center" valign="bottom">1/5<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Arm weakness (also temporarily)<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">85 (25%)<hr/></td><td align="center" valign="bottom">260 (75%)<hr/></td><td align="center" valign="bottom">1/5<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Every cut or injury with bleeding<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">224 (65%)<hr/></td><td align="center" valign="bottom">121 (35%)<hr/></td><td align="center" valign="bottom">1/5<hr/></td></tr><tr><td align="left" valign="bottom">13<hr/></td><td align="left" valign="bottom">Important situation to inform others about OAT<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Overall<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">1<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Dental visits<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">312 (90%)<hr/></td><td align="center" valign="bottom">33 (10%)<hr/></td><td align="center" valign="bottom">1/5<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Pharmacist<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">93 (27%)<hr/></td><td align="center" valign="bottom">252 (73%)<hr/></td><td align="center" valign="bottom">1/5<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Before injections<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">156 (45%)<hr/></td><td align="center" valign="bottom">189 (55%)<hr/></td><td align="center" valign="bottom">1/5<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Any new prescription medication<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">191 (55%)<hr/></td><td align="center" valign="bottom">154 (45%)<hr/></td><td align="center" valign="bottom">1/5<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x02022; Before invasive medical procedures<hr/></td><td align="center" valign="bottom">Yes<hr/></td><td align="center" valign="bottom">305 (88%)<hr/></td><td align="center" valign="bottom">40 (12%)<hr/></td><td align="center" valign="bottom">1/5<hr/></td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center"><bold>Maximum score</bold></td><td align="center"><bold>13</bold></td></tr></tbody></table><table-wrap-foot><p>OAT oral anticoagulation therapy, n.a. non applicable. *non-response was treated as incorrect answer.</p></table-wrap-foot></table-wrap></sec><sec><title>Overall 13-item score and self-rated knowledge</title><p>Participants rated their knowledge about OAT as excellent (9%), good (47%), moderate (36%) and poor (8%) (Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>). The median overall score was 6.8 (IQR 5.2-8.1). There was a small statistically significant association between self-rated knowledge and age below 65&#x000a0;years towards a higher overall-score in univariate analysis. Patients who rated their knowledge as excellent had a median score of 7.8 (IQR 6.6&#x02013; 8.9) and those who rated their knowledge as poor of merely 5.6 (IQR 3.8 &#x02013; 6.6). In univariate analyses higher education and lower age were statistically significant related to higher score, but not gender, history of prior OAT related complications (Figure&#x000a0;<xref ref-type="fig" rid="F2">2</xref>). The observed small differences for age and education remained associated in multivariate analysis (Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>). Age had a negative coefficient of &#x02212;0.044 with each year of age. The 21 patients who did not know why they were taking OAT had on average 1.8 points less (p &#x0003c;0.001) on the overall score disregarding this item.There were additionally 22 caregivers participating as substitutes for patients in this study (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>). The data on these substitutes has not been included in the general analysis to avoid bias. Overall they achieved a better median score than patients. But the numbers of caring relatives was too low for meaningful statistical inference.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Association of the 13-item knowledge score with age, gender, years of education (dichotomized to smaller, and larger or equal 10 years), fear of bleeding, history of prior OAT related complications and self-rated knowledge.</p></caption><graphic xlink:href="1471-2296-15-104-2"/></fig><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Factors associated with the 13-item knowledge score oforal anticoagulation therapy (n&#x02009;=&#x02009;345)</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom">&#x000a0;<hr/></th><th colspan="2" align="center" valign="bottom"><bold>Univariate</bold><hr/></th><th colspan="2" align="center" valign="bottom"><bold>Multivariate</bold><hr/></th></tr><tr><th align="left"><bold>Factor</bold></th><th align="center"><bold>Effect (SE)</bold></th><th align="center"><bold>p-value</bold></th><th align="center"><bold>Effect (SE)</bold></th><th align="center"><bold>p-value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Age (in years)<hr/></td><td align="center" valign="bottom">&#x02212;0.054 (0.1)<hr/></td><td align="center" valign="bottom">&#x0003c;0.01<hr/></td><td align="center" valign="bottom">&#x02212;0.044 (0.01)<hr/></td><td align="center" valign="bottom">&#x0003c;0.001<hr/></td></tr><tr><td align="left" valign="bottom">Gender (women vs. men)<hr/></td><td align="center" valign="bottom">&#x02212;0.11 (0.23)<hr/></td><td align="center" valign="bottom">0.64<hr/></td><td align="center" valign="bottom">0.02 (0.23)<hr/></td><td align="center" valign="bottom">0.92<hr/></td></tr><tr><td align="left" valign="bottom">Education<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x0003c; 10&#x000a0;years education vs. &#x02265; 10&#x000a0;years education<hr/></td><td align="center" valign="bottom">&#x02212;0.68 (0.27)<hr/></td><td align="center" valign="bottom">0.01<hr/></td><td align="center" valign="bottom">&#x02212;0.74 (0.26)<hr/></td><td align="center" valign="bottom">0.004<hr/></td></tr><tr><td colspan="5" align="left" valign="top">Self-rated knowledge<hr/></td></tr><tr><td align="left" valign="bottom">Good vs poor<hr/></td><td align="center" valign="bottom">2.47 (0.40)<hr/></td><td rowspan="3" align="center" valign="top">&#x0003c;0.001<hr/></td><td align="center" valign="bottom">2.29 (0.56)<hr/></td><td rowspan="3" align="center" valign="top">&#x0003c;0.01<hr/></td></tr><tr><td align="left" valign="bottom">Excellent vs poor<hr/></td><td align="center" valign="bottom">1.63 (0.42)<hr/></td><td align="center" valign="bottom">1.44 (0.45)<hr/></td></tr><tr><td align="left" valign="bottom">Moderate vs poor<hr/></td><td align="center" valign="bottom">1.24 (0.42)<hr/></td><td align="center" valign="bottom">1,06 (0.46)<hr/></td></tr><tr><td align="left" valign="bottom">history of OAT related complications none vs complications<hr/></td><td align="center" valign="bottom">0.04 (0.41)<hr/></td><td align="center" valign="bottom">0.93<hr/></td><td align="center" valign="bottom">&#x02212;0.28 (0.39)<hr/></td><td align="center" valign="bottom">0.47<hr/></td></tr><tr><td colspan="5" align="left" valign="bottom">Fear of bleeding<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;Fully agree vs disagree entirely<hr/></td><td align="center" valign="bottom">&#x02212;0.32 (0.33)<hr/></td><td rowspan="3" align="center" valign="top">0.53</td><td align="center" valign="bottom">&#x02212;0.12 (0.32)<hr/></td><td rowspan="3" align="center" valign="top">0.51</td></tr><tr><td align="left" valign="bottom">&#x02003;&#x000a0;Agree vs disagree entirely<hr/></td><td align="center" valign="bottom">0.09 (0.35)<hr/></td><td align="center" valign="bottom">0.28 (0.34)<hr/></td></tr><tr><td align="left">&#x02003;&#x000a0;Do not agree vs disagree entirely</td><td align="center">0.026 (0.35)</td><td align="center">&#x02212;0.13 (0.32)</td></tr></tbody></table><table-wrap-foot><p>OAT oral anticoagulation therapy.</p></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><sec><title>Summary of the main results</title><p>The results of our survey on patient knowledge show relevant knowledge gaps affecting safe and effective OAT. There was a discrepancy between self-rated knowledge and evaluated actual knowledge. Many participants did not recognize symptoms of emergency situations and had poor awareness of drug interactions, particularly regarding over the counter medication (OTC) and other factors influencing the effects of oral anticoagulants. The overall results are unsatisfying and concerning given that a low level of patient knowledge about OAT is the major cause for bleeding complications [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. Lower levels of education, older age and unawareness about the indication for OAT were associated with lower knowledge about OAT.</p></sec><sec><title>Meaning of the results and comparison with literature</title><p>More than half of the patients rated their knowledge on OAT as good or excellent. Despite a correlation between self-evaluation and overall score the actual knowledge was overall low and poor in many safety relevant areas. This confirms findings of many smaller studies [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B22">22</xref>].</p><p>The majority of patients in our survey knew why they were receiving OAT. Not knowing the indication for OAT was a predictor for poor knowledge. Therefore asking patients why they are taking OAT might be useful to identify patients with an urgent need for instructions. A Spanish study and an Italian study observed that the time spent in the therapeutic range was lower in elderly patients not aware of their indication for OAT [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. This is in line with our finding that older age is associated with a lower number of correct answers. This was also observed by others [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. Although one study found that older age was not associated with an increased risk for bleeding complications [<xref ref-type="bibr" rid="B8">8</xref>], others observed a higher incidence of both bleeding and thromboembolic events with advancing age [<xref ref-type="bibr" rid="B7">7</xref>]. Cognitive impairment in elderly patients has been associated with inadequate INR control [<xref ref-type="bibr" rid="B23">23</xref>].</p><p>Only one third of the participants were aware that patients on OAT should follow a regular diet of salad and vegetables to ensure steady vitamin K supply. It has been shown that eating a diet high in vitamin K, reduces the risk of INR measurements in the subtherapeutic range [<xref ref-type="bibr" rid="B24">24</xref>]. A significant proportion (11%) was possibly misinformed and assumed that they should avoid vegetables. Avoiding vegetables to minimize variation in vitamin K intake is not compatible with a healthy diet, as recommended by current guidelines [<xref ref-type="bibr" rid="B25">25</xref>]. This dietary restriction is frequently perceived as a significant reduction in quality of life by many patients [<xref ref-type="bibr" rid="B26">26</xref>].</p><p>We observed a low awareness of drugs affecting the pharmacodynamics of OAT, particularly with OTC medication and herbal medicines. Popular herbal medicines like ginkgo biloba extracts and St. John&#x02019;s wort can affect the risk of bleeding [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. It is known that aspirin and NSAIDs increase bleeding risk, when used in combination with OAT [<xref ref-type="bibr" rid="B29">29</xref>]. Most participants did not know which OTC analgesic is safe for patients with OAT and even worse some indicated they would buy aspirin or other OTC NSAIDs. Only 20% were aware that paracetamol (acetaminophen) is considered the safest OTC analgesic for patients on OAT with phenprocoumon [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. This lack of knowledge is particularly worrisome since two thirds of the participants indicated they would not inform pharmacists about concomitant use of OAT when purchasing OTC medication. However, most participants would inform dentists and physicians before undergoing invasive medical procedures.</p><p>More than half of the participants did not recognize emergency situations such as symptoms of stroke or bleeding complications as an emergency situation in which they should seek immediate medical attention. Several studies have demonstrated that awareness of symptoms of stroke and recognition of stroke as an emergency in the general populations is low [<xref ref-type="bibr" rid="B31">31</xref>]. A group of patients with increased risk of stroke should have higher awareness in order to take appropriate action, if needed.</p></sec><sec><title>Implications for practice</title><p>Patients who have already experienced complications related to OAT should be offered instructions or should seek instructions themselves to avoid future complications. However, no higher levels of knowledge were observed in this patient group.</p><p>Overall the results of our survey are worrisome and call for structured programs to ensure patient knowledge necessary for safe and effective OAT. It cannot be assumed that one educational intervention is sufficient to maintain necessary knowledge. Although we did not formally assess previous educational activities on OAT, we are aware of the fact that many patients in our sample had been taking OAT for a number of years and had been exposed some form of formal or informal education, regarding their therapy. Therefore periodical reassessment might be necessary. The best strategy for an education program about oral anticoagulation has not been determined yet [<xref ref-type="bibr" rid="B10">10</xref>]. An Italian study evaluated the short-term effects of an educational program that did not improve the time spent in the therapeutic range in the short term [<xref ref-type="bibr" rid="B32">32</xref>]. In contrast, a French study could show that an education program lowers the complication rate of patients on OAT [<xref ref-type="bibr" rid="B33">33</xref>]. A systematic review on the effectiveness of educational interventions to improve the proportion of time spent in the therapeutic range was inconclusive [<xref ref-type="bibr" rid="B11">11</xref>]. The included studies were too small to make inferences on complications. Many questions about the best strategy to educate anticoagulated patients remain to be answered. However significant differences in health care systems and the management of OAT will most likely result in different solutions.</p></sec><sec><title>Strength and limitations</title><p>To our knowledge this is the largest study, assessing patient knowledge about OAT in a representative sample of primary care patients [<xref ref-type="bibr" rid="B11">11</xref>]. Previous studies on patient knowledge were conducted in hospitals or with mostly younger patients [<xref ref-type="bibr" rid="B22">22</xref>] often within the frame of patient self-monitoring [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B34">34</xref>]. The results of these studies can therefore not be generalized to the majority of elderly patients [<xref ref-type="bibr" rid="B9">9</xref>]. Studies assessing patient knowledge are prone to selection bias. However, we have a high contact and participation rate and comparison of age and gender did not show statistically significant differences of contacted patients and refusing patients compared to participants. We did not inquire about previous education on OAT since there is no generally established education program for OAT in Germany [<xref ref-type="bibr" rid="B4">4</xref>]. Although we did not assess the duration of OAT, we believe that the majority of patients included in this study have been taking OAT for several years.</p></sec></sec><sec sec-type="conclusions"><title>Conclusions</title><p>We demonstrate that patients in the general practice setting have relevant knowledge gaps, potentially affecting safe and effective OAT. GPs should be aware that most patients overestimate their knowledge. There is a need to assess patient knowledge and for effective education program which might need to be repeated periodically. Education programs should focus on drug interactions with non-prescription drugs, dietary advice and recognition of emergency situations. This need for education will persist even when vitamin-K antagonist will be replaced with new drugs.</p></sec><sec><title>Abbreviations</title><p>GP: General practitioner; INR: International normalized ratio; IQR: Interquartile range; NSAIDs: Non-steroidal anti-inflammatory drugs; OAT: Oral anticoagulation.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests. Stefan Vormfelde is employee of Novartis since February 2014, thus after manuscript submission and without influence on any part of the paper.</p></sec><sec><title>Authors&#x02019; contributions</title><p>Funding for the study was obtained by JFC and SVV. All authors were involved in the design and conduct of the study. The analysis of data was the main responsibility of TF and SS. All authors contributed to manuscript drafting and revision and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2296/15/104/prepub">http://www.biomedcentral.com/1471-2296/15/104/prepub</ext-link></p></sec></body><back><sec><title>Acknowledgement</title><p>We are grateful to all participating practices and patients.</p><sec><title>Funding</title><p>The trial was funded by the German Ministry of Health (Project number 2509 ATS 005) within in the &#x0201c;National action plan for drug safety in Germany&#x0201d; (Aktionsplan des Bundesministeriums f&#x000fc;r Gesundheit zur Verbesserung der Arzneimitteltherapiesicherheit (AMTS) in Deutschland) <ext-link ext-link-type="uri" xlink:href="http://www.akdae.de/AMTS/index.html">http://www.akdae.de/AMTS/index.html</ext-link>.</p></sec></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Rich</surname><given-names>MW</given-names></name><article-title>Epidemiology of atrial fibrillation</article-title><source>J Interv Card Electrophysiol</source><year>2009</year><volume>25</volume><fpage>3</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s10840-008-9337-8</pub-id><pub-id pub-id-type="pmid">19160031</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Camm</surname><given-names>AJ</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name><name><surname>De Caterina</surname><given-names>R</given-names></name><name><surname>Savelieva</surname><given-names>I</given-names></name><name><surname>Atar</surname><given-names>D</given-names></name><name><surname>Hohnloser</surname><given-names>SH</given-names></name><name><surname>Hindricks</surname><given-names>G</given-names></name><name><surname>Kirchhof</surname><given-names>P</given-names></name><name><surname>Bax</surname><given-names>JJ</given-names></name><name><surname>Baumgartner</surname><given-names>H</given-names></name><name><surname>Ceconi</surname><given-names>C</given-names></name><name><surname>Dean</surname><given-names>V</given-names></name><name><surname>Deaton</surname><given-names>C</given-names></name><name><surname>Fagard</surname><given-names>R</given-names></name><name><surname>Funck-Brentano</surname><given-names>C</given-names></name><name><surname>Hasdai</surname><given-names>D</given-names></name><name><surname>Hoes</surname><given-names>A</given-names></name><name><surname>Kirchhof</surname><given-names>P</given-names></name><name><surname>Knuuti</surname><given-names>J</given-names></name><name><surname>Kolh</surname><given-names>P</given-names></name><name><surname>McDonagh</surname><given-names>T</given-names></name><name><surname>Moulin</surname><given-names>C</given-names></name><name><surname>Popescu</surname><given-names>BA</given-names></name><name><surname>Reiner</surname><given-names>Z</given-names></name><name><surname>Sechtem</surname><given-names>U</given-names></name><name><surname>Sirnes</surname><given-names>PA</given-names></name><name><surname>Tendera</surname><given-names>M</given-names></name><name><surname>Torbicki</surname><given-names>A</given-names></name><name><surname>Vahanian</surname><given-names>A</given-names></name><collab>ESC Committee for Practice Guidelines (CPG)</collab><etal/><article-title>2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association</article-title><source>Eur Heart J</source><year>2012</year><volume>33</volume><fpage>2719</fpage><lpage>2747</lpage><pub-id pub-id-type="pmid">22922413</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Ryd&#x000e9;n</surname><given-names>LE</given-names></name><name><surname>Curtis</surname><given-names>AB</given-names></name><name><surname>Ellenbogen</surname><given-names>KA</given-names></name><name><surname>Halperin</surname><given-names>JL</given-names></name><name><surname>Le Heuzey</surname><given-names>JY</given-names></name><name><surname>Kay</surname><given-names>GN</given-names></name><name><surname>Lowe</surname><given-names>JE</given-names></name><name><surname>Olsson</surname><given-names>SB</given-names></name><name><surname>Prystowsky</surname><given-names>EN</given-names></name><name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></name><name><surname>Jacobs</surname><given-names>AK</given-names></name><name><surname>Adams</surname><given-names>CD</given-names></name><name><surname>Anderson</surname><given-names>JL</given-names></name><name><surname>Antman</surname><given-names>EM</given-names></name><name><surname>Nishimura</surname><given-names>R</given-names></name><name><surname>Ornato</surname><given-names>JP</given-names></name><name><surname>Page</surname><given-names>RL</given-names></name><name><surname>Riegel</surname><given-names>B</given-names></name><name><surname>Priori</surname><given-names>SG</given-names></name><name><surname>Blanc</surname><given-names>JJ</given-names></name><name><surname>Budaj</surname><given-names>A</given-names></name><name><surname>Camm</surname><given-names>AJ</given-names></name><name><surname>Dean</surname><given-names>V</given-names></name><name><surname>Deckers</surname><given-names>JW</given-names></name><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>McGregor</surname><given-names>K</given-names></name><name><surname>Metra</surname><given-names>M</given-names></name><name><surname>Morais</surname><given-names>J</given-names></name><collab>European Heart Rhythm Association</collab><etal/><article-title>ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation)</article-title><source>J Am Coll Cardiol</source><year>2006</year><volume>48</volume><fpage>854</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2006.07.009</pub-id><pub-id pub-id-type="pmid">16904574</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Saal</surname><given-names>K</given-names></name><name><surname>Hoffmann</surname><given-names>B</given-names></name><name><surname>Blauth</surname><given-names>E</given-names></name><name><surname>Rohe</surname><given-names>J</given-names></name><name><surname>Beyer</surname><given-names>M</given-names></name><name><surname>Harder</surname><given-names>S</given-names></name><name><surname>Gerlach</surname><given-names>FM</given-names></name><article-title>Analyse des Behandlungsprozesses bei der oralen Antikoagulationstherapie zur Identifikation von Sicherheitsproblemen in der haus&#x000e4;rztlichen Versorgung. [Analysis of the process of oral anti-coagulation therapy for the identification of safety problems in primary care]</article-title><source>Z Allg Med</source><year>2009</year><volume>85</volume><fpage>148</fpage><lpage>155</lpage></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Wyse</surname><given-names>DG</given-names></name><article-title>Bleeding while starting anticoagulation for thromboembolism prophylaxis in elderly patients with atrial fibrillation</article-title><source>Circulation</source><year>2007</year><volume>115</volume><fpage>2684</fpage><lpage>2686</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.704122</pub-id><pub-id pub-id-type="pmid">17533193</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Kagansky</surname><given-names>N</given-names></name><name><surname>Knobler</surname><given-names>H</given-names></name><name><surname>Rimon</surname><given-names>E</given-names></name><name><surname>Ozer</surname><given-names>Z</given-names></name><name><surname>Levy</surname><given-names>S</given-names></name><article-title>Safety of anticoagulation therapy in well-informed older patients</article-title><source>Arch Intern Med</source><year>2004</year><volume>164</volume><fpage>2044</fpage><lpage>2050</lpage><pub-id pub-id-type="doi">10.1001/archinte.164.18.2044</pub-id><pub-id pub-id-type="pmid">15477441</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Torn</surname><given-names>M</given-names></name><name><surname>Bollen</surname><given-names>WL</given-names></name><name><surname>van der Meer</surname><given-names>FJ</given-names></name><name><surname>van der Wall</surname><given-names>EE</given-names></name><name><surname>Rosendaal</surname><given-names>FR</given-names></name><article-title>Risks of oral anticoagulant therapy with increasing age</article-title><source>Arch Intern Med</source><year>2005</year><volume>165</volume><fpage>1527</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.1001/archinte.165.13.1527</pub-id><pub-id pub-id-type="pmid">16009869</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Copland</surname><given-names>M</given-names></name><name><surname>Walker</surname><given-names>ID</given-names></name><name><surname>Tait</surname><given-names>RC</given-names></name><article-title>Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation</article-title><source>Arch Intern Med</source><year>2001</year><volume>161</volume><fpage>2125</fpage><lpage>2128</lpage><pub-id pub-id-type="doi">10.1001/archinte.161.17.2125</pub-id><pub-id pub-id-type="pmid">11570942</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Heneghan</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>A</given-names></name><name><surname>Perera</surname><given-names>R</given-names></name><article-title>Self-monitoring trialist collaboration. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data</article-title><source>Lancet</source><year>2012</year><volume>379</volume><fpage>322</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(11)61294-4</pub-id><pub-id pub-id-type="pmid">22137798</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Wofford</surname><given-names>JL</given-names></name><name><surname>Wells</surname><given-names>MD</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><article-title>Best strategies for patient education about anticoagulation with warfarin: a systematic review</article-title><source>BMC Health Serv Res</source><year>2008</year><volume>8</volume><fpage>40</fpage><pub-id pub-id-type="doi">10.1186/1472-6963-8-40</pub-id><pub-id pub-id-type="pmid">18275605</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Clarkesmith</surname><given-names>DE</given-names></name><name><surname>Pattison</surname><given-names>HM</given-names></name><name><surname>Lane</surname><given-names>DA</given-names></name><article-title>Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation</article-title><source>Cochrane Database Syst Rev</source><year>2013</year><volume>6</volume><comment>CD008600</comment></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Estrada</surname><given-names>CA</given-names></name><name><surname>Martin-Hryniewicz</surname><given-names>M</given-names></name><name><surname>Peek</surname><given-names>BT</given-names></name><name><surname>Collins</surname><given-names>C</given-names></name><name><surname>Byrd</surname><given-names>JC</given-names></name><article-title>Literacy and numeracy skills and anticoagulation control</article-title><source>Am J Med Sci</source><year>2004</year><volume>328</volume><fpage>88</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1097/00000441-200408000-00004</pub-id><pub-id pub-id-type="pmid">15311167</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Hua</surname><given-names>TD</given-names></name><name><surname>Vormfelde</surname><given-names>SV</given-names></name><name><surname>Abed</surname><given-names>MA</given-names></name><name><surname>Schneider-Rudt</surname><given-names>H</given-names></name><name><surname>Sobotta</surname><given-names>P</given-names></name><name><surname>Friede</surname><given-names>T</given-names></name><name><surname>Chenot</surname><given-names>JF</given-names></name><article-title>Practice nursed-based, individual and video-assisted patient education in oral anticoagulation - protocol of a cluster-randomized controlled trial</article-title><source>BMC Fam Pract</source><year>2011</year><volume>12</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/1471-2296-12-17</pub-id><pub-id pub-id-type="pmid">21477372</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Zeolla</surname><given-names>MM</given-names></name><name><surname>Brodeur</surname><given-names>MR</given-names></name><name><surname>Dominelli</surname><given-names>A</given-names></name><name><surname>Haines</surname><given-names>ST</given-names></name><name><surname>Allie</surname><given-names>ND</given-names></name><article-title>Development and validation of an instrument to determine patient knowledge: the oral anticoagulation knowledge test</article-title><source>Ann Pharmacother</source><year>2006</year><volume>40</volume><fpage>633</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1345/aph.1G562</pub-id><pub-id pub-id-type="pmid">16551766</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Jank</surname><given-names>S</given-names></name><name><surname>Bertsche</surname><given-names>T</given-names></name><name><surname>Herzog</surname><given-names>W</given-names></name><name><surname>Haefeli</surname><given-names>WE</given-names></name><article-title>Patient knowledge on oral anticoagulants: results of a questionnaire survey in Germany and comparison with the literature</article-title><source>Int J Clin Pharmacol Ther</source><year>2008</year><volume>46</volume><fpage>280</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.5414/CPP46280</pub-id><pub-id pub-id-type="pmid">18541124</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="other"><name><surname>Bergert</surname><given-names>FW</given-names></name><name><surname>Braun</surname><given-names>M</given-names></name><name><surname>Conrad</surname><given-names>D</given-names></name><name><surname>Ehrental</surname><given-names>K</given-names></name><name><surname>Fenner</surname><given-names>N</given-names></name><name><surname>Fe&#x000df;ler</surname><given-names>J</given-names></name><name><surname>Gross</surname><given-names>J</given-names></name><name><surname>Gundermann</surname><given-names>K</given-names></name><name><surname>Hesse</surname><given-names>H</given-names></name><name><surname>H&#x000fc;ttner</surname><given-names>U</given-names></name><name><surname>Kluther</surname><given-names>B</given-names></name><name><surname>Langheinrich</surname><given-names>W</given-names></name><name><surname>Liesenfeld</surname><given-names>A</given-names></name><name><surname>Luther</surname><given-names>E</given-names></name><name><surname>Pchalek</surname><given-names>R</given-names></name><name><surname>Seffin</surname><given-names>J</given-names></name><name><surname>Sterzing</surname><given-names>A</given-names></name><name><surname>Wolfring</surname><given-names>HJ</given-names></name><name><surname>Zimmermann</surname><given-names>U</given-names></name><article-title>Haus&#x000e4;rztliche Leitlinie Antikoagulation. [General practice guideline anticoagulation]</article-title><year>2009</year><comment><ext-link ext-link-type="uri" xlink:href="http://www.pmvforschungsgruppe.de/pdf/03_publikationen/antikoagulation_ll.pdf">http://www.pmvforschungsgruppe.de/pdf/03_publikationen/antikoagulation_ll.pdf</ext-link></comment></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Ericsson</surname><given-names>K</given-names></name><name><surname>Simon</surname><given-names>H</given-names></name><article-title>Verbal reports as data</article-title><source>Psychol Rev</source><year>1980</year><volume>87</volume><fpage>215</fpage><lpage>251</lpage></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Winans</surname><given-names>ARM</given-names></name><name><surname>Rudd</surname><given-names>KM</given-names></name><name><surname>Triller</surname><given-names>D</given-names></name><article-title>Assessing anticoagulation knowledge in patients new to warfarin therapy</article-title><source>Ann Pharmacother</source><year>2010</year><volume>44</volume><fpage>1152</fpage><lpage>1157</lpage><pub-id pub-id-type="doi">10.1345/aph.1P092</pub-id><pub-id pub-id-type="pmid">20571105</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Henn Cde</surname><given-names>B</given-names></name><name><surname>Rabelo</surname><given-names>ER</given-names></name><name><surname>Boaz</surname><given-names>M</given-names></name><name><surname>De Souza</surname><given-names>EN</given-names></name><article-title>Knowledge on chronic oral anticoagulation of patients followed up in a specialized outpatient clinic</article-title><source>Rev Gaucha Enferm</source><year>2008</year><volume>29</volume><fpage>207</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">18822752</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Barcellona</surname><given-names>D</given-names></name><name><surname>Contu</surname><given-names>P</given-names></name><name><surname>Marongiu</surname><given-names>F</given-names></name><article-title>Patient education and oral anticoagulant therapy</article-title><source>Haematologica</source><year>2002</year><volume>87</volume><fpage>1081</fpage><lpage>1086</lpage><pub-id pub-id-type="pmid">12368164</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Tang</surname><given-names>EO</given-names></name><name><surname>Lai</surname><given-names>CS</given-names></name><name><surname>Lee</surname><given-names>KK</given-names></name><name><surname>Wong</surname><given-names>RS</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Chan</surname><given-names>TY</given-names></name><article-title>Relationship between patients&#x02019; warfarin knowledge and anticoagulation control</article-title><source>Ann Pharmacother</source><year>2003</year><volume>37</volume><fpage>34</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">12503930</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Khudair</surname><given-names>IF</given-names></name><name><surname>Hanssens</surname><given-names>YI</given-names></name><article-title>Evaluation of patient knowledge on warfarin in outpatient anticoagulation clinics in a teaching hospital in Qatar</article-title><source>Saudi Med J</source><year>2010</year><volume>31</volume><fpage>672</fpage><lpage>677</lpage><pub-id pub-id-type="pmid">20563367</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>van Deelen</surname><given-names>BA</given-names></name><name><surname>van den Bemt</surname><given-names>PM</given-names></name><name><surname>Egberts</surname><given-names>TC</given-names></name><name><surname>van &#x02019;t Hoff</surname><given-names>A</given-names></name><name><surname>Maas</surname><given-names>HA</given-names></name><article-title>Cognitive impairment as determinant for sub-optimal control of oral anticoagulation treatment in elderly patients with atrial fibrillation</article-title><source>Drugs Aging</source><year>2005</year><volume>22</volume><fpage>353</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.2165/00002512-200522040-00007</pub-id><pub-id pub-id-type="pmid">15839723</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Rombouts</surname><given-names>EK</given-names></name><name><surname>Rosendaal</surname><given-names>FR</given-names></name><name><surname>van der Meer</surname><given-names>FJ</given-names></name><article-title>Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy</article-title><source>Br J Haematol</source><year>2010</year><volume>149</volume><fpage>598</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2010.08108.x</pub-id><pub-id pub-id-type="pmid">20151978</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="other"><article-title>Nutrition and Food Security Programme WHO Regional Office for Europe: food based dietary guidelines in the WHO European Region</article-title><year>2003</year><comment><ext-link ext-link-type="uri" xlink:href="http://www.euro.who.int/__data/assets/pdf_file/0017/150083/E79832.pdf">http://www.euro.who.int/__data/assets/pdf_file/0017/150083/E79832.pdf</ext-link></comment></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Casais</surname><given-names>P</given-names></name><name><surname>Meschengieser</surname><given-names>SS</given-names></name><name><surname>Sanchez-Luceros</surname><given-names>A</given-names></name><name><surname>Lazzari</surname><given-names>MA</given-names></name><article-title>Patients&#x02019; perceptions regarding oral anticoagulation therapy and its effect on quality of life</article-title><source>Curr Med Res Opin</source><year>2005</year><volume>21</volume><fpage>1085</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1185/030079905X50624</pub-id><pub-id pub-id-type="pmid">16004677</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Bent</surname><given-names>S</given-names></name><name><surname>Goldberg</surname><given-names>H</given-names></name><name><surname>Padula</surname><given-names>A</given-names></name><name><surname>Avins</surname><given-names>AL</given-names></name><article-title>Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature: a case report and systematic review of the literature</article-title><source>J Gen Intern Med</source><year>2005</year><volume>20</volume><fpage>657</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1007/s11606-005-0114-4</pub-id><pub-id pub-id-type="pmid">16050865</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Shalansky</surname><given-names>S</given-names></name><name><surname>Lynd</surname><given-names>L</given-names></name><name><surname>Richardson</surname><given-names>K</given-names></name><name><surname>Ingaszewski</surname><given-names>A</given-names></name><name><surname>Kerr</surname><given-names>C</given-names></name><article-title>Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis</article-title><source>Pharmacotherapy</source><year>2007</year><volume>27</volume><fpage>1237</fpage><lpage>1247</lpage><pub-id pub-id-type="doi">10.1592/phco.27.9.1237</pub-id><pub-id pub-id-type="pmid">17723077</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Schalekamp</surname><given-names>T</given-names></name><name><surname>Klungel</surname><given-names>OH</given-names></name><name><surname>Souverein</surname><given-names>PC</given-names></name><name><surname>de Boer</surname><given-names>A</given-names></name><article-title>Effect of oral antiplatelet agents on major bleeding in users of coumarins</article-title><source>Thromb Haemost</source><year>2008</year><volume>100</volume><fpage>1076</fpage><lpage>1083</lpage><pub-id pub-id-type="pmid">19132233</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Fattinger</surname><given-names>K</given-names></name><name><surname>Frisullo</surname><given-names>R</given-names></name><name><surname>Masche</surname><given-names>U</given-names></name><name><surname>Braunschweig</surname><given-names>S</given-names></name><name><surname>Meier</surname><given-names>PJ</given-names></name><name><surname>Roos</surname><given-names>M</given-names></name><article-title>No clinically relevant drug interaction between paracetamol and phenprocoumon based on a pharmacoepidemiological cohort study in medical inpatients</article-title><source>Eur J Clin Pharmacol</source><year>2002</year><volume>57</volume><fpage>863</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1007/s00228-001-0404-7</pub-id><pub-id pub-id-type="pmid">11936705</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Nicol</surname><given-names>MB</given-names></name><name><surname>Thrift</surname><given-names>AG</given-names></name><article-title>Knowledge of risk factors and warning signs of stroke</article-title><source>Vasc Health Risk Manag</source><year>2005</year><volume>1</volume><fpage>137</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.2147/vhrm.1.2.137.64085</pub-id><pub-id pub-id-type="pmid">17315400</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Barcellona</surname><given-names>D</given-names></name><name><surname>Contu</surname><given-names>P</given-names></name><name><surname>Marongiu</surname><given-names>F</given-names></name><article-title>A &#x0201c;two-step&#x0201d; educational approach for patients taking oral anticoagulants does not improve therapy control</article-title><source>J Thromb Thrombolysis</source><year>2006</year><volume>22</volume><fpage>185</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1007/s11239-006-9027-2</pub-id><pub-id pub-id-type="pmid">17115269</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Blaise</surname><given-names>S</given-names></name><name><surname>Satger</surname><given-names>B</given-names></name><name><surname>Fontaine</surname><given-names>M</given-names></name><name><surname>Yver</surname><given-names>J</given-names></name><name><surname>Rastel</surname><given-names>D</given-names></name><name><surname>Toffin</surname><given-names>L</given-names></name><name><surname>Seinturier</surname><given-names>C</given-names></name><name><surname>Ramos</surname><given-names>M</given-names></name><name><surname>Bosson</surname><given-names>JL</given-names></name><name><surname>Pernod</surname><given-names>G</given-names></name><collab>GRANTED</collab><article-title>&#x000c9;valuation d&#x02019;un programme d&#x02019;&#x000e9;ducation th&#x000e9;rapeutique pour les traitements anticoagulants oraux: exp&#x000e9;rience du r&#x000e9;seau Ville-H&#x000f4;pital GRANTED du secteur Sud-Is&#x000e8;re. [Evaluation of an education program for patients taking oral anticoagulants: experience of the Granted network in Is&#x000e8;re]</article-title><source>J Mal Vasc</source><year>2009</year><volume>34</volume><fpage>346</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1016/j.jmv.2009.07.088</pub-id><pub-id pub-id-type="pmid">19782487</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Sawicki</surname><given-names>PT</given-names></name><article-title>A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation</article-title><source>JAMA</source><year>1999</year><volume>281</volume><fpage>145</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1001/jama.281.2.145</pub-id><pub-id pub-id-type="pmid">9917117</pub-id></mixed-citation></ref></ref-list></back></article>